Sigilon Therapeutics has hired Bioverativ chief global therapeutics operations officer, Rogerio Vivaldi, as CEO. Online This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance. Sigilon is poised to move its cell-based therapeutics implants to phase one trials, with a focus on diabetes, haemophilia and lysosomal storage disorders. The company said it expects the acquisition of Bioverativ will add more than $US1 billion in annual revenue by 2020.
Sigilon Therapeutics has hired Bioverativ chief global therapeutics operations officer, Rogerio Vivaldi, as CEO. Sigilon is poised to move its cell-based therapeutics implants to phase one trials, with a focus on diabetes, haemophilia and lysosomal storage disorders. The company said it expects the acquisition of Bioverativ will add more than $US1 billion in annual revenue by 2020.